Conditions We Address

High Cholesterol & Cardiovascular Risk.

Join Now ↗

What is it.

Cardiovascular disease remains the leading cause of death globally. Cholesterol is a key risk factor, but the standard NHS panel (total cholesterol, LDL, HDL, triglycerides) provides only a partial view. The particles that carry LDL — particularly small, dense LDL and elevated ApoB — are the true atherogenic drivers.

Why does it happen.

LDL particles become atherogenic when they are small and dense (produced in insulin-resistant states), oxidised (driven by inflammation and poor diet), or present in excess (ApoB elevation). Lipoprotein(a) is a genetically determined lipid particle with independently high cardiovascular risk — rarely measured in standard care. Triglycerides and the TG/HDL ratio reflect insulin resistance and metabolic risk. Homocysteine damages endothelial cells. ADMA/SDMA indicate endothelial dysfunction.

How AdeaHealth helps.

We run the full cardiovascular biomarker panel — going beyond total cholesterol to ApoB, Lp(a), particle size, the Omega-3 Index, and endothelial function markers. The programme addresses diet (seed oil reduction, anti-inflammatory pattern), omega-3 status, metabolic health, and lifestyle factors.

Start with a free discovery call.

Join Now ↗

What we test and measure.

ApoB: total atherogenic particle load — more predictive than LDL-C alone
Lipoprotein(a) [Lp(a)]: genetically determined; independently doubles cardiovascular risk
LDL-P & small LDL-P: particle number and size via NMR fractionation
TG/HDL molar ratio: insulin resistance and cardiovascular risk
Atherogenic Index of Plasma (AIP): composite cardiovascular risk

Omega-3 Index: EPA + DHA; <4% associated with high cardiovascular risk
Homocysteine: endothelial damage; target <10 µmol/L
hs-CRP: vascular inflammation
ADMA & SDMA: endothelial function
CT Coronary Angiography: structural arterial assessment (Longevity+)

What you can expect.

A complete cardiovascular risk picture — not a partial snapshot. Intervention targets identified drivers, and progress is tracked against repeat biomarker testing where requested. Clients with clinically elevated Lp(a) or ApoB are referred to our endocrinology partner.